Anti-Hemophilic Factor VIII Concentrate from Canada
A lyophilized concentrate of coagulation Factor VIII derived from human plasma, used therapeutically for hemophilia A treatment. Classified under HTS 3002.90.52 as an other blood fraction prepared for therapeutic uses via biotechnological purification. It replaces missing clotting factors in patients.
Duty Rate — Canada → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• Include lot-specific release certificates from FDA or equivalent for biologics import clearance
• Maintain ultra-low temperature shipping records (-80°C) to preserve potency during transit
• Beware of quota restrictions on plasma products; verify annual allocations with Customs